Recent Quotes

My Watchlist

Indicators

Currencies

International

Treasuries

Jasper Therapeutics, Inc. - Class A Common Stock (NQ:JSPR)

1.470 -0.010 (-0.68%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	263,165
Open	1.470
Bid (Size)	1.470 (200)
Ask (Size)	1.550 (1,000)
Prev. Close	1.480
Today's Range	1.470 - 1.530
52wk Range	1.390 - 7.190
Shares Outstanding	736,213
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Here are the top movers in Thursday's session. ↗

January 08, 2026

Via Chartmill

These stocks are gapping in today's session ↗

January 08, 2026

Via Chartmill

Performance

YTD	-20.1%	-20.1%
1 Month	-19.7%	-19.7%
3 Month	-30.0%	-30.0%
6 Month	-50.5%	-50.5%
1 Year	-76.3%	-76.3%

More News

These stocks have an unusual volume in today's session ↗

December 03, 2025

Via Chartmill

$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside

December 02, 2025

Via AB Newswire

These stocks are moving in today's pre-market session ↗

December 02, 2025

Via Chartmill

What's going on in today's after hours session ↗

December 01, 2025

Via Chartmill

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

November 22, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

November 18, 2025

Via NewMediaWire

JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

November 18, 2025

Via TheNewswire.com

JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit

November 18, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, KBR, Spirit, and Molina of the Upcoming Deadlines and Urges Investors to Contact the Firm

November 17, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

November 17, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

November 17, 2025

From Schall Law

Via GlobeNewswire

JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR

November 16, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

November 14, 2025

Via NewMediaWire

JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

November 14, 2025

Via TheNewswire.com

JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

November 13, 2025

From Schall Law

Via GlobeNewswire

CoreWeave Bulls Should Brace For 'Wild, Lumpy, Volatile Ride,' JPMorgan Says ↗

November 11, 2025

Via Benzinga

Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, KBR, Spirit, and Molina to Contact the Firm About their Rights

November 10, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

November 10, 2025

From Schall Law

Via GlobeNewswire

JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

November 09, 2025

Via TheNewswire.com

JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Jasper Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

November 09, 2025

Via NewMediaWire

JSPR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit

November 09, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

JSPR Deadline: Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders to Contact the Firm for Information About Their Rights

November 07, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

November 06, 2025

From Schall Law

Via GlobeNewswire

Frequently Asked Questions

Is Jasper Therapeutics, Inc. - Class A Common Stock publicly traded?

Yes, Jasper Therapeutics, Inc. - Class A Common Stock is publicly traded.

What exchange does Jasper Therapeutics, Inc. - Class A Common Stock trade on?

Jasper Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock?

The ticker symbol for Jasper Therapeutics, Inc. - Class A Common Stock is JSPR on the Nasdaq Stock Market

What is the current price of Jasper Therapeutics, Inc. - Class A Common Stock?

The current price of Jasper Therapeutics, Inc. - Class A Common Stock is 1.470

When was Jasper Therapeutics, Inc. - Class A Common Stock last traded?

The last trade of Jasper Therapeutics, Inc. - Class A Common Stock was at 02/02/26 04:00 PM ET

What is the market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock?

The market capitalization of Jasper Therapeutics, Inc. - Class A Common Stock is 1.08M

How many shares of Jasper Therapeutics, Inc. - Class A Common Stock are outstanding?

Jasper Therapeutics, Inc. - Class A Common Stock has 1M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.